| Autor: |
Beehler CC; Private practice, Ft. Myers, Florida; †Medical University of South Carolina, Charleston, South Carolina; ‡University of Utah, Salt Lake City, Utah; §Nalle Clinic, Charlotte, North Carolina; ∥Phillips Eye Institute, Minneapolis, Minnesota; ¶University of South Florida, Tampa, Florida; and # Allergan, Inc., Irvine, California, U.S.A., Stewart WC, Macdonald DK, Croyle TA, Ostrov CS, Rosanelli EG, Crandall AS, Iacono TL, Lue JC, Kelley EP |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of glaucoma [J Glaucoma] 1992 Winter; Vol. 1 (4), pp. 237-42. |
| DOI: |
10.1097/00061198-199201040-00005 |
| Abstrakt: |
Treatment with noncardioselective beta-adrenoceptor antagonists (e.g., 0.5% timolol or 0.5% levobunolol) is standard practice for lowering elevated intraocular pressure (IOP). However, because there are risks and side effects associated with the use of these agents, a lower, yet still effective, dose may be preferred. We gave 0.5% timolol twice daily for 30 days to 143 patients. In a double-masked, randomized fashion, we then assigned patients to continue to receive 0.5% timolol twice daily or 0.25% levobunolol twice daily for 8 weeks. The mean unmedicated baseline IOP for both groups was approximately 25 mm Hg. After 30 days of timolol pretreatment, the mean IOP in both groups decreased to approximately 19 mm Hg (p = 0.210). After the 30-day timolol pretreatment period, and subsequent randomization to either 0.5% timolol or 0.25% levobunolol treatment, there was little change in overall mean IOP (0.03 mm Hg decrease for levobunolol, 0.06 mm Hg increase for timolol; p = 0.811) from the timolol pretreatment baseline. One patient assigned to the timolol treatment group was terminated from the study due to inadequate control of IOP. We conclude that the mean IOP lowering effect of 0.25% levobunolol is equivalent to 0.5% timolol, and switching patients from twice-daily 0.5% timolol to twice-daily 0.25% levobunolol poses no significant risk of decreased ocular hypotensive efficacy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
